Developer docs
API playgroundTry for free, no card

Search company profiles

Pharmaxo

Full company profile

uuid0024bj9

Namestring
Pharmaxo
Legal namestring
Qualasept Pharmaxo Holdings Limited
Websiteurl
pharmaxo.com
Company typeenum
Private
Founded yearint
2004
Descriptiontext

Pharmaxo is a UK-based pharmaceutical group operating through three wholly-owned subsidiaries—Bath ASU, Pharmaxo Healthcare, and Pharmaxo Scientific—headquartered in Corsham, Wiltshire. Founded circa 2004 (originally as Qualasept/Bath ASU) and rebranded from QPHL to Pharmaxo in October 2022, the group has specialized for over two decades in aseptic compounding services, manufacturing patient-specific and dose-banded chemotherapy, central intravenous additives (CIVAS), and patient-controlled analgesia products. Since July 2024, Pharmaxo has operated as a wholly-owned subsidiary of Australia's Icon Group, integrating it into a global cancer-care platform alongside Slade Health. The group employs over 400 people in the South West of England and produces more than 2,000 sterile pharmaceutical products daily.

The company's revenue model rests on two pillars. Bath ASU generates revenue through contract aseptic manufacturing of pharmaceutical specials supplied to NHS trusts, other pharmaceutical companies, and private providers, with pricing set via NHS frameworks and direct enterprise quotes. Pharmaxo Healthcare operates a clinical homecare business delivering high-tech treatments (oncology, enzyme replacement, biologics) directly to patients in their homes and community settings, alongside a Mobile Treatment Centre fleet and a Virtual Nurse remote training service. No public revenue or pricing schedule exists beyond disclosed entry-level production operator wages of £24,823 annually. The group holds the Queen's Award for Enterprise (2019), carbon-neutral certification through Carbonfund.org, and most recently the 2026 Moondance Cancer Awards Collaborating with Partners Award with Cardiff and Vale UHB.

Customer acquisition is driven by enterprise field sales targeting NHS trusts, integrated care systems, and pharmaceutical companies; distribution channels include direct NHS hospital partnerships, homecare field service, mobile treatment units deployed on-site, and paediatric home/school delivery for enzyme replacement therapy. R&D at Pharmaxo Scientific focuses on pharmaceutical stability research via Knowledge Transfer Partnerships with the University of Bath. In September 2025, Bath ASU validated and implemented MALDI-TOF equipment reducing microbiological contaminant identification time from days to approximately ten minutes—a quality-control capability enhancement implemented in the first full year under Icon Group ownership.

Short descriptiontext

Pharmaxo is a UK-based pharmaceutical group specializing in aseptic compounding (chemotherapy, CIVAS, PCA) and clinical homecare delivery, serving NHS trusts, pharmaceutical companies, and patients since 2004 as a subsidiary of Australia's Icon Group.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersCorsham, United Kingdom
HQ citystring
Corsham
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical manufacturing services, aseptic compounding services, clinical homecare services, chemotherapy compounding, pharmaceutical specials manufacturing
Industry4 codes
PRIMARYHLAFALAE
Compounding Pharmacies (Sterile/Non-Sterile)
Healthcare & Life Sciences/Healthcare Providers & Systems/Pharmacy & Medication Management Services
SECONDARYHLAFALAC
Specialty Pharmacies (Complex/High-Cost Therapies)
Healthcare & Life Sciences/Healthcare Providers & Systems/Pharmacy & Medication Management Services
SECONDARYHSABALAG
Injectables & Specialty Medication Support (e.g., insulin, biologics)
Home & Personal Services/Elder Care & In-Home Care Services/Medication Management & In-Home Pharmacy Support
SECONDARYHSABALAH
In-Home Infusion Pharmacy Support & Coordination
Home & Personal Services/Elder Care & In-Home Care Services/Medication Management & In-Home Pharmacy Support
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Pharmaceutical Compounding and Clinical Homecare Services
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Pharmaceutical Manufacturing
TypeOne Time License
Description

Bath ASU provides pharmaceutical specials manufacturing including patient-specific chemotherapy, dose banded batch chemotherapy, central intravenous additive service, and patient-controlled analgesia products. Manufactures thousands of life-changing pharmaceutical products weekly.

pharmaxo.com
2Clinical Homecare Services
TypeManaged Services
Description

Pharmaxo Healthcare delivers high-tech treatments to patients in their own homes and in community-based settings, working with NHS, pharmaceutical companies, private medical providers, and self-funding patients.

pharmaxo.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Supply Chain, Infrastructure, Marketing or Sales
Pricing details1 tier
1Production Operator entry-level position
ModelOtherBilling cadenceAnnual
Notes

Starting Salary: £24,823 per year. Full-time 37.5 hours per week with rotating shifts. Additional benefits include company pension (6% contribution matched with 8%), free breakfast, 25 days holiday plus bank holidays, life assurance, cycle to work scheme, free gym classes, and staff discounts.

pharmaxo.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Pharmaxo is a UK pharmaceutical group providing aseptic compounding and clinical homecare services. Through Bath ASU it manufactures sterile pharmaceutical specials including patient-specific chemotherapy, dose-banded chemotherapy, central intravenous additives, and patient-controlled analgesia products. Through Pharmaxo Healthcare it delivers high-tech treatments to patients in their own homes and community settings, and operates Mobile Treatment Centres and virtual nursing support.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Bath ASU produces over 2000 sterile pharmaceutical products daily
+2 more records
Product overview1 text field

Pharmaxo Group operates as a leading provider of aseptic compounding services and clinical homecare across the UK, comprising three main operating subsidiaries: Bath ASU (pharmaceutical specials manufacturer producing sterile injectable products including chemotherapy and patient-specific medications), Pharmaxo Healthcare (clinical homecare provider delivering treatments to patients in their homes and community settings), and Pharmaxo Scientific (research and development focused on stability research). The group also offers Mobile Treatment Centres for on-site clinic delivery and Virtual Nurses for remote patient training and support, serving NHS trusts, pharmaceutical companies, and patients across multiple therapy areas including oncology, haematology, immunology, and rare diseases.

Product and service5 records
1Bath ASU Aseptic Manufacturing Services
CategoryPharmaceutical Manufacturing / Aseptic Compounding
Description

Pharmaceutical specials manufacturing service providing patient-specific chemotherapy, dose-banded batch chemotherapy, central intravenous additive service (CIVAS), and patient-controlled analgesia products, producing thousands of sterile pharmaceutical products weekly for NHS trusts and pharmaceutical companies across the UK.

2Pharmaxo Healthcare Clinical Homecare Services
CategoryClinical Homecare / Pharmacy Services
Description

Specialist pharmacy and clinical homecare service delivering high-tech treatments to patients in their own homes and community-based settings, working with NHS trusts, pharmaceutical companies, private medical providers, and self-funding patients across multiple therapy areas.

3Mobile Treatment Centre
CategoryClinical Homecare / Mobile Infusion Services
Description

Custom-designed mobile clinic providing immunotherapy and chemotherapy treatments in convenient community locations, enabling NHS trusts to transition patients to out-of-hospital care with full clinical service including manufacturing, dispensing, clinic management, and nurse provision.

4Virtual Nursing Service
CategoryClinical Homecare / Remote Patient Training
Description

Virtual nursing team providing patient training via secure video calling to support self-administration of drugs at home for patients across the UK across multiple therapy areas.

5Paediatric Enzyme Replacement Therapy Service
CategoryClinical Homecare / Paediatric Specialty Services
Description

Specialist home and school-based enzyme replacement therapy service for paediatric patients with lysosomal storage disorders including mucopolysaccharidosis type I and II (Hurler and Hunter syndromes) and Gaucher disease, managed by a paediatric lead nurse and delivered by trained paediatric nurses.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-25
Description

Pharmaxo Healthcare partnered with Cardiff and Vale University Health Board for the Delivering Myeloma Treatment at Home initiative, winning the 2026 Moondance Cancer Awards Collaborating with Partners Award.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-07-09
Description

Pharmaxo joined Icon Group in a strategic partnership marking the establishment of a global compounding operator and Icon's pharmaceutical entry in the UK. Icon Group operates integrated cancer care centres throughout Australia, South East Asia and the UK and owns Slade Health. Ian Muir remains as CEO reporting into Icon Group's global structure. Chris Watt serves as strategic advisor on European strategy.

3University Hospitals of Leicester NHS Trust
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-12-19
Description

Partnership with University Hospitals of Leicester NHS Trust to provide immunotherapy and chemotherapy treatments at Glenfield Hospital through Pharmaxo's Mobile Treatment Centre. Pharmaxo provides full clinical service including manufacturing, dispensing, clinic management and nurse provision.

pharmaxo.com
4Frimley Health and Care ICS
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership with Frimley Health and Care ICS supporting their Community Medical Diagnostic Unit (CMDU) service. GP Triage partner East Berkshire Primary Care also involved in the partnership.

pharmaxo.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Icon Group's strategic partnership with Nuffield Health to bring more cancer treatment capacity to underserved communities across the UK.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

NHS referral centre for paediatric enzyme replacement therapy service. First paediatric patient referred in May 2023. Excellent clinical relationship pivotal to service growth.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Icon Group's compounding arm in Australia and New Zealand, delivering over 1.2 million infusions annually. Now a sister company to Pharmaxo post-2024 acquisition, providing the most direct comparison for global compounding economics and capability.

TypeDirect peer
Description

UK clinical homecare specialist providing home administration of complex medicines including oncology and rare disease therapies. Direct competitor to Pharmaxo Healthcare in the NHS homecare market.

TypeBroad incumbent
Description

Global healthcare company with large sterile injectable manufacturing and home infusion therapy businesses. Comparable in sterile compounding scale and clinical homecare delivery, but operates as a broad incumbent across multiple product lines.

TypeBroad incumbent
Description

UK-listed pharmaceutical services company providing unlicensed and specialty medicines, clinical trial supply, and homecare services. Comparable business model combining pharmaceutical supply, compounding access, and homecare delivery.

TypeOthers
Description

UK pharmaceutical distribution and specialist services company serving NHS and pharma manufacturers. Functions as an adjacent supplier/distributor in the same NHS pharmaceutical supply chain.

TypeBroad incumbent
Description

Global medical device and pharmaceutical manufacturer with significant sterile compounding, infusion solutions, and clinical nutrition offerings. Overlaps with Bath ASU's aseptic manufacturing but at much greater scale and across broader geographies.

TypeDirect peer
Description

UK specialist pharmaceutical manufacturer focused on aseptic compounding, sterile injectables, and bespoke medicines. Comparable in scale, regulatory profile, and NHS-contracted sterile manufacturing focus.

8Healthcare at Home
TypeDirect peer
Description

UK clinical homecare provider offering home-based drug administration, nursing, and patient support services. Direct competitor to Pharmaxo Healthcare's clinical homecare model.

TypeDirect peer
Description

UK-based specialist aseptic compounding pharmacy producing CIVAS, chemotherapy, and patient-specific sterile products for NHS hospitals. Direct overlap with Bath ASU's core compounding offering and NHS customer base.

TypeDirect peer
Description

UK clinical homecare and pharmacy services provider delivering treatments to patients' homes, overlapping directly with Pharmaxo Healthcare's home infusion and nursing services.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries3 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Pharmaxo

Pharmaceutical Compounding and Clinical Homecare Servicespharmaxo.com

Pharmaxo is a UK-based pharmaceutical group specializing in aseptic compounding (chemotherapy, CIVAS, PCA) and clinical homecare delivery, serving NHS trusts, pharmaceutical companies, and patients since 2004 as a subsidiary of Australia's Icon Group.

What Pharmaxo does

Pharmaxo is a UK-based pharmaceutical group operating through three wholly-owned subsidiaries—Bath ASU, Pharmaxo Healthcare, and Pharmaxo Scientific—headquartered in Corsham, Wiltshire. Founded circa 2004 (originally as Qualasept/Bath ASU) and rebranded from QPHL to Pharmaxo in October 2022, the group has specialized for over two decades in aseptic compounding services, manufacturing patient-specific and dose-banded chemotherapy, central intravenous additives (CIVAS), and patient-controlled analgesia products. Since July 2024, Pharmaxo has operated as a wholly-owned subsidiary of Australia's Icon Group, integrating it into a global cancer-care platform alongside Slade Health. The group employs over 400 people in the South West of England and produces more than 2,000 sterile pharmaceutical products daily.

The company's revenue model rests on two pillars. Bath ASU generates revenue through contract aseptic manufacturing of pharmaceutical specials supplied to NHS trusts, other pharmaceutical companies, and private providers, with pricing set via NHS frameworks and direct enterprise quotes. Pharmaxo Healthcare operates a clinical homecare business delivering high-tech treatments (oncology, enzyme replacement, biologics) directly to patients in their homes and community settings, alongside a Mobile Treatment Centre fleet and a Virtual Nurse remote training service. No public revenue or pricing schedule exists beyond disclosed entry-level production operator wages of £24,823 annually. The group holds the Queen's Award for Enterprise (2019), carbon-neutral certification through Carbonfund.org, and most recently the 2026 Moondance Cancer Awards Collaborating with Partners Award with Cardiff and Vale UHB.

Customer acquisition is driven by enterprise field sales targeting NHS trusts, integrated care systems, and pharmaceutical companies; distribution channels include direct NHS hospital partnerships, homecare field service, mobile treatment units deployed on-site, and paediatric home/school delivery for enzyme replacement therapy. R&D at Pharmaxo Scientific focuses on pharmaceutical stability research via Knowledge Transfer Partnerships with the University of Bath. In September 2025, Bath ASU validated and implemented MALDI-TOF equipment reducing microbiological contaminant identification time from days to approximately ten minutes—a quality-control capability enhancement implemented in the first full year under Icon Group ownership.

Pharmaxo firmographics

Firmographics
Name
Pharmaxo
Legal name
Qualasept Pharmaxo Holdings Limited
Website
https://pharmaxo.com
Company type
Private
Founded year
2004
Operating status
Operating
Headcount range
101–250 employees
Short description
Pharmaxo is a UK-based pharmaceutical group specializing in aseptic compounding (chemotherapy, CIVAS, PCA) and clinical homecare delivery, serving NHS trusts, pharmaceutical companies, and patients since 2004 as a subsidiary of Australia's Icon Group.
Ownership category
akta.pro rank

Pharmaxo industry classification

Industry
Product category
Pharmaceutical Compounding and Clinical Homecare Services
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAFALAE
Compounding Pharmacies (Sterile/Non-Sterile)
Healthcare & Life Sciences/Healthcare Providers & Systems/Pharmacy & Medication Management Services
SECONDARYHLAFALAC
Specialty Pharmacies (Complex/High-Cost Therapies)
Healthcare & Life Sciences/Healthcare Providers & Systems/Pharmacy & Medication Management Services
SECONDARYHSABALAG
Injectables & Specialty Medication Support (e.g., insulin, biologics)
Home & Personal Services/Elder Care & In-Home Care Services/Medication Management & In-Home Pharmacy Support
SECONDARYHSABALAH
In-Home Infusion Pharmacy Support & Coordination
Home & Personal Services/Elder Care & In-Home Care Services/Medication Management & In-Home Pharmacy Support

Keywords

  • Pharmaceutical manufacturing services
  • Aseptic compounding services
  • Clinical homecare services
  • Chemotherapy compounding
  • Pharmaceutical specials manufacturing

Where Pharmaxo is headquartered

Location

Headquarters

HQ city
Corsham
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

Pharmaxo business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Supply Chain, Infrastructure, Marketing or Sales

Revenue model

  1. Pharmaceutical Manufacturing: Bath ASU provides pharmaceutical specials manufacturing including patient-specific chemotherapy, dose banded batch chemotherapy, central intravenous additive service, and patient-controlled analgesia products. Manufactures thousands of life-changing pharmaceutical products weekly.
  2. Clinical Homecare Services: Pharmaxo Healthcare delivers high-tech treatments to patients in their own homes and in community-based settings, working with NHS, pharmaceutical companies, private medical providers, and self-funding patients.

Pricing tiers

ModelBillingPrice
OtherAnnualProduction Operator entry-level position

Go-to-market motion1 record

Distribution channels4 records

Marketing channels4 records

Pharmaxo product offering

Product offering

Core offering

Pharmaxo is a UK pharmaceutical group providing aseptic compounding and clinical homecare services. Through Bath ASU it manufactures sterile pharmaceutical specials including patient-specific chemotherapy, dose-banded chemotherapy, central intravenous additives, and patient-controlled analgesia products. Through Pharmaxo Healthcare it delivers high-tech treatments to patients in their own homes and community settings, and operates Mobile Treatment Centres and virtual nursing support.

Product overview

Pharmaxo Group operates as a leading provider of aseptic compounding services and clinical homecare across the UK, comprising three main operating subsidiaries: Bath ASU (pharmaceutical specials manufacturer producing sterile injectable products including chemotherapy and patient-specific medications), Pharmaxo Healthcare (clinical homecare provider delivering treatments to patients in their homes and community settings), and Pharmaxo Scientific (research and development focused on stability research). The group also offers Mobile Treatment Centres for on-site clinic delivery and Virtual Nurses for remote patient training and support, serving NHS trusts, pharmaceutical companies, and patients across multiple therapy areas including oncology, haematology, immunology, and rare diseases.

Differentiator

Problem solved

Functional benefit

Products and services

  • Bath ASU Aseptic Manufacturing Services Pharmaceutical specials manufacturing service providing patient-specific chemotherapy, dose-banded batch chemotherapy, central intravenous additive service (CIVAS), and patient-controlled analgesia products, producing thousands of sterile pharmaceutical products weekly for NHS trusts and pharmaceutical companies across the UK.
  • Pharmaxo Healthcare Clinical Homecare Services Specialist pharmacy and clinical homecare service delivering high-tech treatments to patients in their own homes and community-based settings, working with NHS trusts, pharmaceutical companies, private medical providers, and self-funding patients across multiple therapy areas.
  • Mobile Treatment Centre Custom-designed mobile clinic providing immunotherapy and chemotherapy treatments in convenient community locations, enabling NHS trusts to transition patients to out-of-hospital care with full clinical service including manufacturing, dispensing, clinic management, and nurse provision.
  • Virtual Nursing Service Virtual nursing team providing patient training via secure video calling to support self-administration of drugs at home for patients across the UK across multiple therapy areas.
  • Paediatric Enzyme Replacement Therapy Service Specialist home and school-based enzyme replacement therapy service for paediatric patients with lysosomal storage disorders including mucopolysaccharidosis type I and II (Hurler and Hunter syndromes) and Gaucher disease, managed by a paediatric lead nurse and delivered by trained paediatric nurses.

Quantifiable outcome

  • Bath ASU produces over 2000 sterile pharmaceutical products daily
  • +2 more outcomes

Companies that use Pharmaxo

Customer profile

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Pharmaxo technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Pharmaxo partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and minor.

  • Cardiff and Vale University Health BoardcoreStrategic or Co-development Partner · 25 June 2026Pharmaxo Healthcare partnered with Cardiff and Vale University Health Board for the Delivering Myeloma Treatment at Home initiative, winning the 2026 Moondance Cancer Awards Collaborating with Partners Award.
  • Icon GroupcoreStrategic or Co-development Partner · 9 July 2024Pharmaxo joined Icon Group in a strategic partnership marking the establishment of a global compounding operator and Icon's pharmaceutical entry in the UK. Icon Group operates integrated cancer care centres throughout Australia, South East Asia and the UK and owns Slade Health. Ian Muir remains as CEO reporting into Icon Group's global structure. Chris Watt serves as strategic advisor on European strategy.
  • University Hospitals of Leicester NHS TrustcoreStrategic or Co-development Partner · 19 December 2023Partnership with University Hospitals of Leicester NHS Trust to provide immunotherapy and chemotherapy treatments at Glenfield Hospital through Pharmaxo's Mobile Treatment Centre. Pharmaxo provides full clinical service including manufacturing, dispensing, clinic management and nurse provision.
  • Frimley Health and Care ICScoreStrategic or Co-development PartnerPartnership with Frimley Health and Care ICS supporting their Community Medical Diagnostic Unit (CMDU) service. GP Triage partner East Berkshire Primary Care also involved in the partnership.
  • Nuffield HealthminorStrategic or Co-development PartnerIcon Group's strategic partnership with Nuffield Health to bring more cancer treatment capacity to underserved communities across the UK.
  • Birmingham Children's HospitalcoreStrategic or Co-development PartnerNHS referral centre for paediatric enzyme replacement therapy service. First paediatric patient referred in May 2023. Excellent clinical relationship pivotal to service growth.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Pharmaxo competitors and assessment

Company assessment

Direct peers

  • Slade Health: Icon Group's compounding arm in Australia and New Zealand, delivering over 1.2 million infusions annually. Now a sister company to Pharmaxo post-2024 acquisition, providing the most direct comparison for global compounding economics and capability.
  • Sciensus (formerly Healthcare at Home Ltd): UK clinical homecare specialist providing home administration of complex medicines including oncology and rare disease therapies. Direct competitor to Pharmaxo Healthcare in the NHS homecare market.
  • Nova Laboratories: UK specialist pharmaceutical manufacturer focused on aseptic compounding, sterile injectables, and bespoke medicines. Comparable in scale, regulatory profile, and NHS-contracted sterile manufacturing focus.
  • Healthcare at Home: UK clinical homecare provider offering home-based drug administration, nursing, and patient support services. Direct competitor to Pharmaxo Healthcare's clinical homecare model.
  • ITH Pharma: UK-based specialist aseptic compounding pharmacy producing CIVAS, chemotherapy, and patient-specific sterile products for NHS hospitals. Direct overlap with Bath ASU's core compounding offering and NHS customer base.
  • Alcura (Alliance Healthcare): UK clinical homecare and pharmacy services provider delivering treatments to patients' homes, overlapping directly with Pharmaxo Healthcare's home infusion and nursing services.

Broad incumbents

  • Baxter International: Global healthcare company with large sterile injectable manufacturing and home infusion therapy businesses. Comparable in sterile compounding scale and clinical homecare delivery, but operates as a broad incumbent across multiple product lines.
  • Clinigen Group: UK-listed pharmaceutical services company providing unlicensed and specialty medicines, clinical trial supply, and homecare services. Comparable business model combining pharmaceutical supply, compounding access, and homecare delivery.
  • B. Braun Medical: Global medical device and pharmaceutical manufacturer with significant sterile compounding, infusion solutions, and clinical nutrition offerings. Overlaps with Bath ASU's aseptic manufacturing but at much greater scale and across broader geographies.

Others

  • Qualasept Bath ASU Suppliers / Mawdsleys: UK pharmaceutical distribution and specialist services company serving NHS and pharma manufacturers. Functions as an adjacent supplier/distributor in the same NHS pharmaceutical supply chain.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Pharmaxo social profiles

Digital presence

Pharmaxo compliance and trust

Trust signal

Compliance3 records

Pharmaxo financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Pharmaxo leadership team

Management profile

Number of profiles

Profiles10 records

Pharmaxo subsidiaries and ownership

Company hierarchy

Subsidiaries3 records

Pharmaxo funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Pharmaxo M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pharmaxo

What does Pharmaxo do?

Pharmaxo is a UK pharmaceutical group providing aseptic compounding and clinical homecare services. Through Bath ASU it manufactures sterile pharmaceutical specials including patient-specific chemotherapy, dose-banded chemotherapy, central intravenous additives, and patient-controlled analgesia products. Through Pharmaxo Healthcare it delivers high-tech treatments to patients in their own homes and community settings, and operates Mobile Treatment Centres and virtual nursing support.

Is Pharmaxo a public or private company?

Pharmaxo is a private company. It is classified as corporate owned and is currently operating.

When was Pharmaxo founded?

Pharmaxo was founded in 2004. It employs 101 to 250 people.

Where is Pharmaxo based?

Pharmaxo is headquartered in Corsham, United Kingdom, in the Europe region.

How does Pharmaxo make money?

Two revenue lines are on record. Pharmaceutical Manufacturing is the primary driver. The others are clinical Homecare Services.

Who are Pharmaxo's main competitors?

Direct peers on record are Slade Health, Sciensus (formerly Healthcare at Home Ltd), Nova Laboratories, Healthcare at Home, ITH Pharma and Alcura (Alliance Healthcare). Broad incumbents are Baxter International, Clinigen Group and B. Braun Medical. Qualasept Bath ASU Suppliers / Mawdsleys is listed as an others.

Does Pharmaxo have an API?

No public API is recorded for Pharmaxo.

What industry is Pharmaxo in?

Pharmaxo's product category is Pharmaceutical Compounding and Clinical Homecare Services. Its primary akta.pro industry code is HLAFALAE, Compounding Pharmacies (Sterile/Non-Sterile), with a secondary code of HLAFALAC, Specialty Pharmacies (Complex/High-Cost Therapies). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals